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Objective: Statin therapy reduces coronary heart disease (CHD) and mortality in individuals with elevated C-reactive protein
(CRP) but low-density lipoprotein cholesterol below the threshold at which statin therapy is recommended. We determined the
proportion of individuals with elevated CRP in whom statin therapy was not indicated, and examined predictors for elevated
CRP in a multi-ethnic Asian population.
Design: We studied 3404 participants (Chinese, Malays and Asian-Indians) without a history of hypercholesterolemia living in
Singapore (mean age±s.d.: 48.9±11.2 years). Eligibility for statin therapy was determined based on the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III (ATPIII)) guideline. CRP was measured by high-sensitivity enzyme-linked immunosorbent assay method. CRP
level greater than 2mgl
 1 was considered as elevated.
Results: Elevated CRP was found in 29.3% participants who were not eligible for statin therapy (n¼2974). Elevated CRP was
more common in females and amongst those of Malay or Asian-Indian ethnicity. Compared with participants with low CRP,
those with elevated CRP were shown to have higher levels of obesity, blood pressure, triglyceride and insulin resistance (IR), but
lower high-density lipoprotein cholesterol levels (all Pso0.001). After multivariate analysis, gender (odds ratio (OR) 3.34 for
females), ethnicity (Malay OR 1.57, 95% confidence interval (CI) 1.25–1.96; Asian-Indian OR 1.97, 95% CI 1.55–2.50), waist
circumference (OR 1.06, 95% CI 1.05–1.07), smoking (OR 1.49, 95% CI 1.08–2.05) and IR (OR 1.14, 95% CI 1.07–1.22) were
significant predictors of CRP (all Ps–valueso0.05).
Conclusion: Routine measurement of CRP identifies a substantial number of Asian individuals at risk of CHD in whom statin
therapy is not currently indicated, particularly in women and certain ethnic groups (Malays and Asian Indians). Weight loss
and smoking cessation are important measures to reduce the proportion of individuals with elevated CRP.
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Introduction
The National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III (ATPIII))
guideline has recommended that patients should be
treated with lipid-lowering therapy if the level of low-density
lipoprotein cholesterol exceeds a specific threshold.
To optimize the cost effectiveness and minimize the risk of
lipid-lowering therapy, these thresholds are calibrated to the
estimated risk for the individual patient, such that the most
intensive therapy is recommended for those at the highest
risk. The NCEP–ATPIII guideline uses the Framingham Risk
Score (FRS), which is the most widely validated and used
cardiovascular risk assessment tool that helps to risk stratify
individuals for future risk of coronary heart disease (CHD).
1
It is increasingly recognized that atherosclerosis is an
inflammatory disease
2 and that C-reactive protein (CRP), as a
marker of inflammation, is associated with elevated risk of
CHD.
3 CRP is not included in the FRS that is used in the Received 3 January 2011; accepted 11 April 2011
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both men
4 and women
5 have shown that for individuals
with the same level of risk assessed using the FRS, individuals
with high CRP have elevated risk of CHD. Most recently, the
JUPITER trial (Justification for the Use of Statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin) showed
that, in patients with elevated CRP (42mgl
 1) but
low-density-lipoprotein cholesterol (LDL-C) levels below
the currently recommended thresholds for initiating lipid
lowering therapy, statin therapy reduced the risk of CHD and
all-cause mortality LDL.
6 The increased risk of CHD with
increasing levels of CRP is also observed in populations in
Asia. However, it should be noted that in several Asian
populations, the level of CRP is much lower than in Western
populations.
7–10 In a study conducted in Japan, individuals
in the top quartile of CRP had over three times increased risk
of CHD,
11 but the median CRP level in this quartile was only
1.47mgl
 1, which was well below the level used as an
inclusion criterion in the JUPITER study. It might be
suggested that the current definitions of elevated CRP and
the findings of the JUPITER study have little relevance to
Asian populations.
To better understand these issues, we examined data
from a large, population-based study, which included three
major ethnic groups (Chinese, Malays and Asian Indians)
living in Singapore. We sought to determine the proportion
and the characteristics of the population with elevated
CRP levels, but LDL-C levels below the currently recom-
mended threshold for statin therapy, as recommended by
the NCEP–ATPIII guideline. We also determined the major
determinants for elevated CRP in this population, as this
may provide information required to implement targeted
screening programs and may point toward other targets for
non-drug intervention.
Subjects and methods
Study design and population
We invited 10747 participants from four population-based,
cross-sectional surveys conducted in Singapore (1982–1998)
to participate in a repeat examination from 2004 to 2007.
The four studies include the Thyroid and Heart Study 1982–
1984,
12 the National Health Survey 1992,
13 the National
University of Singapore Heart Study 1993–1995
14 and the
National Health Survey 1998.
15 Briefly, all studies included a
random sample of individuals from the Singapore popula-
tion, with disproportionate sampling stratified by ethnicity
to increase the number in the minority ethnic groups
(Malays and Asian Indians). Participants’ deceased at the
time of follow-up were excluded (n¼559). Also excluded
were six participants who had emigrated and 102 who had
errors in the records of their National Registry Identity Card.
Participants were contacted to obtain an appointment for
investigators to administer the questionnaire at the subject’s
home. Home visits were attempted on three different
occasions before a subject was deemed non-contactable
(n¼2306). Of those participants who could be contacted,
30 (0.4%) refused to participate. All participants were invited
to attend a health examination for additional tests and
collection of biological specimens shortly after the home
visit. A total of 7744 (76.8% response rate) participants
completed the questionnaire; 5164 of them (66.7% of those
who completed the questionnaire or 51.2% of all eligible
participants) also attended the health examination. During
the period from 2 April 2005 to 20 February 2006, because
of limited resources, ankle-brachial index was determined
only for every alternate Chinese participant but for all
participants from other ethnic groups. Data for peripheral
vascular disease, one of the CHD risk equivalents, were,
therefore, not available for 1050 participants and they were
thus excluded from the analyses.
Ethics approval was obtained from two institutional
review boards (the National University of Singapore
and the Singapore General Hospital). Informed consent was
obtained before the study was conducted.
Data collection
Data on demographic and lifestyle factors (alcohol con-
sumption, smoking), as well as medical history (including
physician-diagnosed hypertension, diabetes mellitus and
hypercholesterolemia), were collected by using interviewer-
administered questionnaires. For the health examination,
participants were examined the morning following a 10-h
overnight fast. Venous blood was drawn and collected in
plain and fluoride oxalate tubes and was stored at 41C for a
maximum of 4h before processing. All biochemical analyses
of blood were carried out at the National University Hospital
Referral Laboratory, which is accredited by the College of
American Pathologists. Serum total cholesterol, triglyceride
and high-density lipoprotein cholesterol were measured by
using an automated autoanalyzer (ADVIA 2400; Bayer
Diagnostics, Tarrytown, NY, USA). LDL-C levels were calcu-
lated using the Friedewald formula. Plasma glucose was
assayed with enzymatic methods (ADVIA 2400) by using
blood collected in fluoride oxalate tubes. The intra-day and
inter-day coefficients of variation for total cholesterol,
triglyceride, high-density lipoprotein cholesterol and plasma
glucose were 0.80–1.57% and 0.93–1.15%, 0–3.85% and
1.27–3.40%, 0.56–0.65% and 1.18–2.00%, 0–0.93% and
1.68–1.83%, respectively. Insulin resistance (IR) was assessed
by the homeostasis model assessment, where IR¼(fasting
insulin in mIUl
 1 fasting glucose in mmoll
 1)/22.5.
CRP was measured using a high-sensitivity enzyme-linked
immunosorbent assay method implemented on the COBAS
Integra 400 from Roche Diagnostics (Rotkreuz, Switzerland).
The intra-assay precision was 0.6–1.3%, whereas the inter-
assay precision was 2.3–3.1%. We defined elevated CRP as
42.0mgl
 1, similar to the criteria that was used in JUPITER
trial.
6 In addition, Jiang et al.
16 found that a CRP level of
2mgl
 1 or more effectively predicted the risk of CHD in the
Chinese population.
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Nutrition and DiabetesHeight was measured, without the subject wearing shoes,
using a wall-mounted stadiometer. Weight was measured in
light clothing using the same digital scale (SECA, model 782-
2321009; Vogel & Halke, Hamburg, Germany) for all
participants. Body mass index was calculated as weight (in
kilogram) divided by height (in meter) squared. An auto-
mated blood pressure monitor (Dinamap Pro100V2;
Criticon, Norderstedt, Germany) was used to take two
blood pressure readings from participants after 5min of rest.
A third reading was performed if the difference between
the two readings of systolic blood pressure was greater than
10mmHg or of diastolic blood pressure was greater than
5mmHg. Mean values of the closest two readings were
calculated. Ankle pressures were measured using a standar-
dized doppler ultrasonic device (8MHz; SmartdopTM 20EX,
Bi-directional blood flow detector, Hadeco, Japan) after a
5-min rest in the supine position. Ankle-brachial index was
calculated as the ratio of the higher of the two systolic
pressures (from posterior tibial and dorsalis pedis) at the
ankle to the average of the right and left brachial artery
pressures.
Definitions
Diabetes mellitus was defined as fasting plasma glucose
X7.0mmoll
 1 or a known history of diabetes mellitus and
currently taking anti-diabetic medications. Hypertension
was defined as a systolic blood pressure greater than
140mmHg or a diastolic blood pressure greater than
90mmHg or a history of hypertension or current use of
antihypertensive medications. Cigarette smoking was de-
fined as individuals who were currently smoking. Peripheral
arterial disease was defined as an ankle-brachial index o0.9.
Each individual was further categorized according to the five
criteria for metabolic syndrome based on the International
Diabetes Federation criteria:
17 triglyceride 41.7mmoll
 1;
high-density lipoprotein cholesterol o1.0mmoll
 1 in men
or o1.3mmoll
 1 in women; blood pressure 4130/85mmHg
or known treatment for hypertension; fasting plasma glucose
45.6mmoll
 1 or known treatment for diabetes; and waist
circumference 480cm in women and 490cm in men.
Individuals showed central obesity, and at least two other
risk factors were classified as metabolic syndrome.
Statistical analysis
We estimated the 10-year risk of CHD for all participants
using the FRS.
1 Participants were assigned to one of the four
risk categories according to the NCEP–ATPIII guideline to
determine eligibility for cholesterol-lowering treatment,
namely a statin therapy.
18 These categories are (1) low
CHD risk: 0–1 risk factor, (2) intermediate low CHD risk: 2þ
risk factors and 10-year risk o10%, (3) intermediate high
CHD risk: 2þ risk factors and 10-year risk 10–20% and (4)
high CHD risk: CHD risk equivalent with 10-year risk 420%
(Figure 1). Participants who required statin therapy were
those with the LDL-C levels above group-specific thresholds
(i.e., LDL-C of 190, 160, 130 and 130mgdl
 1 for risk category
group 1 through 4, respectively). Participants who did not
meet the NCEP–ATPIII guideline for initiation of statin
therapy (i.e., not eligible for statin therapy) were further
subdivided into two groups based on CRP cutoff level
of 2mgl
 1. Serum CRP levels were limited to maximum of
10mgl
 1 as per the American Heart Association/Centers for
Disease Control guideline, which states that a level of
410mgl
 1 may indicate an acute inflammatory state or
inflammatory disease.
19
For continuous variables, one-way analysis of variance was
used to test the differences between participants with low
CRP (p2mgl
 1) versus high CRP (42.0mgl
 1) levels. The
w
2-test was used to compare proportions of categorical
variables between the groups. Odds ratios (ORs) and 95%
confidence intervals (CIs) were obtained from a logistic
regression model, which examined predictors for CRP in
participants who were not eligible for cholesterol-lowering
therapy. All data analyses were conducted using Stata 10 for
Windows (Stata Corporation, College Station, TX, USA). All
values are given as mean (standard deviation) unless stated
otherwise. All statistical tests were two-sided, with a
statistical significance defined as Po0.05.
Results
For this study, we excluded participants who were on statin
treatment (n¼395), had missing data on history of heart
disease, stroke, hypertension, diabetes mellitus and hyper-
cholesterolemia, BMI and smoking (n¼315). Thus, data on
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Figure 1 Proportions of participants (%) who were eligible and not eligible
for statin therapy, based on CHD risk categories as recommended by the
NCEP-ATPIII guideline. The participants who were not eligible for statin
therapy were further divided into low CRP (p2mgl
 1) and high CRP
(42mgl
 1) group. Group 1Flow CHD risk (0–1 risk factor), n¼1946.
Group 2Fintermediate low CHD risk (2þ risk factors and Framingham 10-
year risk o10%), n¼619. Group 3Fintermediate high CHD risk (2þ risk
factors and Framingham 10-year risk 10–20%), n¼353. Group 4Fhigh CHD
risk (CHD risk equivalent with 10-year risk 420%), n¼486.
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(o10mgl
 1) measurements were used in the analysis.
Overall, 1946 (57.2%) participants had low CHD risk, 619
(18.2%) had intermediate low CHD risk, 353 (10.4%) inter-
mediate high CHD risk and 486 (14.2%) had high CHD risk.
Approximately 12.6% would qualify for statin therapy, based
on the NCEP–ATPIII guideline. The proportion of those in
whom a statin was indicated increased as the risk level
increased, reaching 56.3% in those who were at high risk
of CHD (Figure 1). A further 29.3% had elevated CRP, even
though statin therapy was not indicated, with a similar
proportion across the various risk categories. The majority
(73.2%) of individuals at low risk also had normal CRP levels.
In Table 1, we compared the characteristics of participants
with and without elevated CRP among those who were not
eligible for statin therapy (n¼2974). The characteristics of
those who did qualify for statin therapy were presented
alongside for comparison. Among those not eligible for
statin therapy, individuals with elevated CRP levels were
more likely to be older, female and of Malay or Asian-Indian
ethnicity. Compared with those with CRP p2mgl
 1,
participants with CRP 42mgl
 1 were more likely to have
hypertension and diabetes mellitus and also had higher
blood pressure, obesity (measured by body mass index or
waist circumference), plasma triglyceride, LDL-cholesterol
and IR (all P-valueso0.001). High-density lipoprotein
cholesterol was lower in those with elevated CRP levels
(Po0.001).
As many of the features associated with elevated CRP were
components of the metabolic syndrome, we also determined
the number of metabolic risk factors according to the
International Diabetes Federation definition of metabolic
syndrome in those with and without elevated CRP (Figure 2).
Table 1 Characteristics of participants who were eligible and were not eligible for statin therapy, based on the NCEP–ATPIII guideline
Participants not eligible for statin therapy Participants eligible
for statin therapy
Low CRP (p2mgl
 1) High CRP (42mgl
 1) P-value*
N 2104 870 430
Female (%) 52.1 61.2 o0.001 35.4
Ethnicity (%) o0.001
Chinese 78.8 21.2 39.8
Malay 61.1 38.9 35.4
Indian 50.3 49.7 24.9
Current smoking
a (%) 9.5 8.9 0.576 28.8
History of hypertension (%) 13.2 21.5 o0.001 27.0
Diabetes mellitus (%) 4.7 9.7 o0.001 31.0
Age, year 47.4 (11.0) 49.6 (10.7) o0.001 54.9 (11.1)
Body mass index (kgm
 2) 22.7 (3.5) 26.0 (4.2) o0.001 25.1 (4.0)
Waist circumference (cm) 80.6 (11.3) 88.4 (10.7) o0.001 89.4 (11.1)
Systolic BP (mmHg) 127.5 (18.8) 133.6 (19.9) o0.001 142.9 (22.9)
Diastolic BP (mmHg) 76.4 (10.4) 78.8 (10.3) o0.001 82.8 (11.1)
Total cholesterol (mgdl
 1) 195.7 (31.2) 197.9 (29.8) 0.106 252.1 (31.1)
Triglyceride (mgdl
 1) 108.5 (72.3) 131.9 (108.7) o0.001 155.9 (69.1)
HDL-C (mgdl
 1) 53.4 (13.8) 48.3 (12.1) o0.001 47.4 (12.3)
LDL-C (mgdl
 1) 117.7 (27.1) 121.1 (25.7) o0.001 170.6 (25.6)
HOMA-IR 1.5 (1.3) 2.4 (2.0) o0.001 2.9 (3.2)
Metabolic syndrome
b (%) 7.7 22.0
Abbreviations: BP, blood pressure; CRP, C-reactive protein; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, insulin resistance based on homeostasis model
assessment; LDL-C, low-density lipoprotein cholesterol. Participants who were not eligible for statin therapy were further divided into low CRP and high CRP group.
*P-value (two-sided) comparing subgroup with CRP p2mgl
 1 versus CRP 42mgl
 1. Data are expressed as mean (standard deviation) or % (proportion of the
group). Continuous variables for the two groups were compared by using Student’s t-test. The w
2-test was used for categorical variables.
aDefined as a yes response
to the questions, ‘Have you ever smoked cigarettes?’ and ‘Do you smoke now?’
bMetabolic syndrome as defined by the International Diabetes Federation.
0.0
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Figure 2 Proportion of participants (%) with varying numbers of cardio-
metabolic risk factors in those with and without elevated C-reactive protein
(CRP). The participants were divided into low CRP (p2mgl
 1) and high CRP
(42mgl
 1) group. The cardio-metabolic risk factors include triglyceride
41.7mmoll
 1, high-density lipoprotein cholesterol o1.0mmoll
 1 in men or
o1.3mmoll
 1 in women, blood pressure 4130/85mmHg or known
treatment for hypertension, fasting plasma glucose 45.6mmoll
 1 or known
treatment for diabetes and waist circumference 480cm in women and
490cm in men.
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or more risk factors compared with those with normal CRP.
The prevalence of metabolic syndrome was higher in
participants with CRP 42mgl
 1 when compared with those
with CRP p2mgl
 1 (22.0 versus 7.7%, Po0.001).
We next performed multivariable logistic regression ana-
lysis to identify independent predictors of elevated CRP
levels in participants who were not eligible for statin therapy
(Table 2). Compared with univariate models, only gender
(female, OR 3.34 95% CI 2.68–4.16), ethnicity (Malays,
OR 1.57 95% CI 1.25–1.96; Asian Indians OR 1.97, 95% CI
1.55–2.50), waist circumference (OR 1.06 95% CI 1.05–1.07)
and IR (OR 1.14 95% CI 1.07–1.22) were statistically
significant (all P-valueso0.001), although the effect of
ethnicity, waist circumference and IR appeared attenuated
compared with the univariate analyses. Interestingly, ciga-
rette smoking became a significant predictor of elevated CRP
levels after adjustment for other factors (OR 1.49, 95% CI
1.08–2.05, P¼0.011).
Discussion
In this study, we observed that 12.6% of our population
qualified for statin therapy, based on the risk of CHD events
estimated using the FRS and their LDL-C levels. Of those who
did not qualify for statin therapy, approximately one-third
had elevated CRP levels (defined as 42mgl
 1). These
individuals were equally distributed across the various
FRS risk categories and some, particularly those in the
intermediate risk group, may benefit from aggressive CHD
risk reduction therapy, including a statin therapy.
19 The
findings from the recently published JUPITER study provided
evidence that statin therapy in these individuals with low
LDL-C levels but elevated CRP conferred a comparable
degree of risk reduction and similar number needed to treat
as other widely accepted interventions for the primary
prevention of cardiovascular disease.
20
We also found that the features of the metabolic syndrome
were more common in the participants with high CRP levels
when compared with those with low CRP levels. This is in
line with other studies that have shown that the metabolic
syndrome is associated with elevated CRP.
21–23 Following
multivariate analysis, we found two independent risk factors
for elevated CRP levels that are modifiable, that is, smoking
and elevated waist circumference. Again, this is in line with a
previous study showing that subjects with metabolic syn-
drome had higher levels of CRP and the main determinant
of the CRP elevation was waist circumference.
24 A recent
systematic review suggests that weight loss, regardless of
whether it occurs through surgical, lifestyle, dietary and/or
exercise intervention, is an effective strategy for lowering CRP
levels.
25 Other studies have also shown that CRP levels are
elevated among smokers and decreased with long-term
smoking cessation.
26,27 Weight loss and smoking cessation
are also effective in reducing IR, and may be particularly
important interventions among those classified as low CHD
risk (i.e., 0 to 1 risk factor or Framingham risk estimate of
o10%), in whom the evidence for statin therapy is limited.
28,29
In this multi-ethnic population, we also found that CRP
levels varied substantially between individuals of different
ethnic groups. When compared with Chinese, elevated CRP
(42mgl
 1) levels were about two times more likely in Asian
Indians and Malays, even after adjustment for other known
variables that might affect CRP levels. This is consistent with
Table 2 Determinants of CRP levels in participants who were not eligible for statin therapy, based on the NCEP–ATPIII guideline
Unadjusted OR P-value Multivariate OR P-value
Gender
Male 1.00 F 1.00 F
Female 1.45 (1.23, 1.70) o0.001 3.34 (2.68, 4.16) o0.001
Race
Chinese 1.00 F 1.00 F
Malays 2.37 (1.94, 2.90) o0.001 1.57 (1.25, 1.96) o0.001
Asian Indians 3.67 (2.98, 4.53) o0.001 1.97 (1.55, 2.50) o0.001
Current smoking 0.92 (0.70, 1.22) 0.577 1.49 (1.08, 2.05) 0.011
History of hypertension 1.81 (1.47, 2.22) o0.001 1.11 (0.85, 1.43) 0.236
Age 1.02 (1.01, 1.03) o0.001 1.00 (0.99, 1.01) 0.381
Waist circumference 1.07 (1.06, 1.08) o0.001 1.06 (1.05, 1.08) o0.001
Systolic BP 1.02 (1.01, 1.02) o0.001 1.00 (1.00, 1.01) 0.396
Total cholesterol 1.11 (1.00, 1.23) 0.036 0.73 (0.30, 1.76) 0.595
Triglyceride 1.004 (1.003, 1.005) o0.001 1.00 (1.00, 1.01) 0.735
HDL-C 0.97 (0.96, 0.98) o0.001 0.99 (0.97, 1.01) 0.390
LDL-C 1.005 (1.002, 1.008) 0.001 1.01 (0.99, 1.04) 0.411
HOMA-IR 1.50 (1.41, 1.59) o0.001 1.14 (1.07, 1.22) o0.001
Abbreviations: BP, blood pressure; CRP, C-reactive protein; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, insulin resistance
based on homeostasis model assessment; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio. Data expressed as OR (95% confidence interval). Bold values
are those with P-value o0.05.
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CHD compared with Malays or Chinese.
30 However, whether
elevated CRP levels have a direct causal relationship with
atherosclerosis or merely reflect a greater burden of athero-
sclerosis in the Asian Indians is yet to be elucidated. Such
ethnic differences were also observed in the Study of
Women’s Health Across the Nation (SWAN) cohort, which
found that CRP levels varied significantly between ethnic
groups, with the highest concentrations seen in African-
American participants, followed in order by Hispanic, White,
Chinese and Japanese participants.
31 Despite the lower CRP
levels in Chinese, we still observed that a substantial
proportion had CRP 42mgdl
 1.
In addition to ethnic differences, female gender is a strong
predictor of CRP levels in this population. This finding
resonates with findings from several other studies, including
the Multi-ethnic study of Atherosclerosis that demonstrated
a higher CRP levels in women compared with men, even
after adjusting for body mass index and other common
confounding variables.
32,33 However, several studies did not
show the gender differences in CRP levels.
34,35 Recently, in a
large population based-sample with accurate adipose tissue
quantification by dual-energy X-ray absorptiometry and
abdominal magnetic resonance imaging, Khera et al.
36
reported that higher CRP levels in women compared with
men might be explained by the differences in the amount of
total fat mass and regional distribution of fat. At this time,
the reasons for higher CRP levels in women remain unclear.
Strengths of the present study include data collected from a
large sample of community-based individuals. The population
also consists of three major ethnic groups residing in
Singapore, which represent several of the largest ethnic groups
in Asia where the burden of cardiovascular disease is increasing
most rapidly.
37 In addition, a comprehensive assessment of
CHD risk factors was available, including an assessment of
peripheral arterial disease. This study has limitations worth
mentioning. Firstly, the cross-sectional nature of our study
does not allow us to estimate the long-term impact of elevated
CRP levels on the risk of CHD after the traditional cardio-
vascular risk factors are taken into account. Secondly, we
measured CRP on a single occasion. This could lead to some
misclassification. However, the proportions of individuals
with elevated CRP level are sufficiently high (B32%) that
even if this were an overestimate, it would remain a significant
problem in the population. Furthermore, we anticipate that
any measurement error would be non-differential in relation
to the risk factors identified and would therefore bias our
findings toward the null hypothesis of no association. Thus,
we do not feel that any misclassification would significantly
alter our conclusions.
In summary, in a multi-ethnic Asian population living in
Singapore, elevated CRP level affects a significant proportion
of individuals who would not qualify for statin therapy
based on the LDL-C levels. This was more common in
women and in those of Malay and Asian-Indian ethnicity.
Whether extending statin therapy to this segment of
population to reduce incidence of CHD is not yet clear.
Even if drug therapy is not recommended, this presence
of elevated CRP should motivate the physician and patient
to reinforce healthy lifestyle, targeted at reducing obesity
and smoking cessation to reduce the proportion of indivi-
duals with elevated CRP levels. These lifestyle interventions
should be integrated in any preventive strategy to reduce the
burden of CHD and may be particularly pertinent to those at
low risk of CHD. Finally, the findings of ethnic and gender
differences in CRP levels merit further investigations and
may shed light on the pathogenesis of atherosclerosis.
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